Financial Contrast: BioCardia (NASDAQ:BCDA) and Capricor Therapeutics (NASDAQ:CAPR)

BioCardia (NASDAQ:BCDA) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares BioCardia and Capricor Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60,000.00	225.33	-$8.23 million	($0.64)	-1.40
Capricor Therapeutics	$22.27 million	25.77	-$105.04 million	($2.45)	-4.03

BioCardia has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCardia has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Profitability

This table compares BioCardia and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Capricor Therapeutics	N/A	-56.71%	-42.71%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BioCardia and Capricor Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1	1	1	0	2.00
Capricor Therapeutics	1	5	5	0	2.36

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 2,699.55%. Capricor Therapeutics has a consensus price target of $29.77, suggesting a potential upside of 201.65%. Given BioCardia’s higher probable upside, equities research analysts clearly believe BioCardia is more favorable than Capricor Therapeutics.

Institutional & Insider Ownership

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Capricor Therapeutics beats BioCardia on 7 of the 13 factors compared between the two stocks.

About BioCardia

BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy. BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.